← All trials
NCT06788236
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 23, 2022
- Primary completion
- Jun 14, 2024
- Completion date
- Sep 19, 2024
- First posted
- Jan 23, 2025
- Last posted
- Apr 9, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aventi Biotechnology Inc.Lead sponsor
- University of UlsanCollaborator
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- Ajou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.